What are Caprelsa’s global sales figures?
Public, company-reported “global sales” numbers for Caprelsa (vandetanib) are typically released through annual reports, quarterly earnings, and investor presentations by the marketing authorization holder(s), rather than in a single consolidated global sales database. The specific global-sales figure depends on the reporting period (full year vs. quarter) and which fiscal year’s filings you mean.
Who sells Caprelsa and how do sales get reported?
Caprelsa is marketed by AstraZeneca (and/or its affiliates) in multiple regions. Sales are usually reported as part of AstraZeneca’s product revenue in geographic segments or as product sales in earnings materials, with “global” referring to the sum across regions covered in company reporting.
How have Caprelsa’s sales changed over time?
Caprelsa’s sales trajectory varies across markets and years based on:
market uptake and treatment-line positioning,
pricing and reimbursement decisions,
competition from newer oncology therapies,
and any label/usage changes over time.
To answer with exact numbers, you need the year (or quarter) and the source type (AstraZeneca annual report vs. earnings deck).
What period should you use for “global sales”?
Common searches that match this query are:
“Caprelsa global sales 2023/2024”
“Caprelsa global sales 2022 (full-year)”
“Caprelsa worldwide revenue in Qx 20xx”
If you tell me the year/quarter you want (and whether you want worldwide revenue or prescription-volume-like metrics), I can format the figures to match how companies report them.
Can you compare Caprelsa global sales to other drugs?
Yes, but comparisons depend on whether you’re comparing:
company revenue (sales in currency),
unit sales (if disclosed),
or market/line-of-therapy share (often not fully disclosed).
With a target year, the comparison can be tied to the same reporting basis.
Share the year and I’ll pull the exact numbers
What do you mean by global sales: full-year (which year) or a specific quarter?